These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 2079473)

  • 1. Gemfibrozil in familial and type V hyperlipidaemias. Report of 3 cases.
    Varthakavi P; Turakhia DP; Sharma S; Salgaonkar DS; Nihalani KD; Joshi VR
    J Assoc Physicians India; 1990 Nov; 38(11):860-2. PubMed ID: 2079473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
    Varthakavi PK; Turakhia DP; Sharma SS; Salgaonkar DS; Nihalani KD; Joshi VR
    J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effect of gemfibrozil on coronary heart disease risk profile of patients with primary combined hyperlipidaemia.
    Athyros VG; Papageorgiou AA; Avramidis MJ; Kontopoulos AG
    Coron Artery Dis; 1995 Mar; 6(3):251-6. PubMed ID: 7788039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of etofibrate and gemfibrozil in combined hyperlipidaemia.
    Wolf HR
    Drugs Exp Clin Res; 1994; 20(3):109-13. PubMed ID: 7956717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.
    Ojala JP; Helve E; Tikkanen MJ
    Cardiology; 1990; 77 Suppl 4():39-49. PubMed ID: 2073671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of gemfibrozil and clofibrate on serum lipids in familial combined hyperlipidemia. A randomized placebo-controlled, double-blind, crossover clinical trial.
    Rabkin SW; Hayden M; Frohlich J
    Atherosclerosis; 1988 Oct; 73(2-3):233-40. PubMed ID: 3056431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society.
    Eur Heart J; 1988 May; 9(5):571-600. PubMed ID: 3402474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of primary mixed hyperlipidemia with lovastatin.
    Vega GL; Grundy SM
    Arch Intern Med; 1990 Jun; 150(6):1313-9. PubMed ID: 2353864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gemfibrozil in the treatment of lipid metabolism disorders].
    Vartanova OA; Aleksandrovskaia TN; Shaldaeva VV
    Klin Med (Mosk); 1994; 72(1):37-41. PubMed ID: 8196321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Lipid therapy in risk patients. Do we concentrate too much on LDL cholesterol?].
    März W
    MMW Fortschr Med; 2005 Apr; 147(14):14. PubMed ID: 15887675
    [No Abstract]   [Full Text] [Related]  

  • 12. Gemfibrozil in dyslipidaemia.
    Kundu SC; Roxy S; Batabyal SK
    J Assoc Physicians India; 1990 Feb; 38(2):156-9. PubMed ID: 2199426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of gemfibrozil treatment on vascular reactivity of streptozotocin-diabetic rat aorta.
    Ozansoy G; Akin FB
    J Pharm Pharmacol; 2004 Feb; 56(2):241-6. PubMed ID: 15005883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemfibrozil treatment increases low-density lipoprotein particle size in Type 2 diabetes mellitus but does not alter in vitro oxidizability.
    O'Neal DN; O'Brien RC; Timmins KL; Grieve GD; Lau KP; Nicholson GC; Kotowicz MA; Best JD
    Diabet Med; 1998 Oct; 15(10):870-7. PubMed ID: 9796889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia.
    Lamendola C; Abbasi F; Chu JW; Hutchinson H; Cain V; Leary E; McLaughlin T; Stein E; Reaven G
    Am J Cardiol; 2005 Jan; 95(2):189-93. PubMed ID: 15642550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus.
    Cominacini L; Garbin U; Pastorino AM; Fratta Pasini A; Campagnola M; De Santis A; Davoli A; Lo Cascio V
    Diabetes Res; 1994; 26(4):173-84. PubMed ID: 7648791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemfibrozil in familial combined hyperlipidaemia: effect of added low-dose cholestyramine on plasma and biliary lipids.
    Odman B; Ericsson S; Lindmark M; Berglund L; Angelin B
    Eur J Clin Invest; 1991 Jun; 21(3):344-9. PubMed ID: 1909637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia.
    Bröijersén A; Eriksson M; Angelin B; Hjemdahl P
    Arterioscler Thromb Vasc Biol; 1995 Jan; 15(1):121-7. PubMed ID: 7749807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of familial combined hyperlipidemia].
    Bruckert E
    Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-symmetric subcutaneous lipomatosis associated with familial combined hyperlipidaemia.
    Rubinstein A; Goor Y; Gazit E; Cabili S
    Br J Dermatol; 1989 May; 120(5):689-94. PubMed ID: 2757931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.